Jose Costa, MD, FACP
Professor Emeritus of Pathology and Senior Research ScientistCards
Appointments
Contact Info
About
Titles
Professor Emeritus of Pathology and Senior Research Scientist
Biography
José Costa, MD, FACP, is Professor Emeritus of Pathology at Yale University School of Medicine and Professeur Honoraire at the University of Lausanne Switzerland. Dr. Costa is an internationally renowned leader in the field of diagnostics of cancer and pathogenesis of tumor formation. Having contributed to the transition from opinion-based medicine to evidence-based diagnosis, he is now making use of novel tools to practice integrative systems pathology, an approach that strives to enable a personalized, predictive and precise diagnosis.
Prior his transition to Emeritus status April 1, 2018, at the Yale School of Medicine, Dr Costa served in several positions of leadership that include: Chief of the Anatomical Pathology Branch at the Clinical Center, NIH Bethesda Md (1980-83); Director of the Institute of Pathology, University of Lausanne, Lausanne, Switzerland (1983-1993); President of the Board of Directors of the Centre Pluridisciplinaire d’Oncologie, Lausanne Switzerland (1985-1992); Director of Anatomical Pathology Yale New Haven Hospital (1993-2007); and Deputy Director of the Yale Comprehensive Cancer Center (1995-2007). He is a sought-after advisor to several academic, research, and health organizations, and has served or currently serves as board member or advisor to several institutions including the ISREC (Swiss Cancer Research Institut); the Ludwig Institut Branch in Lausanne; the Deutsche Krebs Forschung Zenter (Heidelberg); the Institut of Molecular Pathology at Porto (Portugal); The Catalan Institut of Oncology [ICO] Barcelona, Spain; the Centro Nacional de Investigacion en Oncologia [CNIO] Madrid,Spain, the Instituto Carlos III, Madrid, Spain, the Center for Virtual Tumor Modeling (Harvard); the NIH Consensus Panels and the NCI’s EDRN in Bethesda, MD, USA.
Throughout his career, Dr. Costa has integrated advances in basic understanding of cancer to the clinical area of diagnosis, prognosis, and early detection. He has contributed over 170 original publications to the technical literature, and is among a small group of investigators using evolutionary and ecological theory to predict tumor behavior. His laboratory investigates the micro-evolutionary dynamics involved in tumor formation and tumor progression using both experimental and theoretical modeling at the systems level. This work has identified novel and promising ways to detect early cancer and ways to follow the changes in tumors under therapy. Dr. Costa is co-inventor of two novel diagnostic technologies and has served in the oversight board of Yale’s Office of Cooperative Research. He has also been involved in the crafting of public-private joint ventures in Switzerland (IP-AMS Labs [1999]), the early launching of Curagen Corporation (New Haven, CT [1996]), the founding of Aureon Biosciences (Yonkers, NY [2001]), VCN (Barcelona, Spain [2005]), and PetaOmics (San Marcos, TX [2014]).
The contributions of Dr. Costa have been recognized by several awards, including a Special Achievement Award from NIH, election as a Fellow to the American Association for the Advancement of Science (2003), the Gold Medal of the International Academy of Pathology. and the Trueta Medal from the Catalan government for contributions to public health.
A firm believer in the dynamics coming from multi-disciplinarity and cooperation, Dr. Costa continues to create an environment that will transform health care and set the standards for the 21st century. He is particularly interested in exploring synergies between academia, private industry, and governmental programs.
Appointments
Other Departments & Organizations
- Larynx Lab
- Pathology
- Pathology and Molecular Medicine
- Pathology Research
- Sarcoma Program
- Yale Cancer Center
- Yale Medicine
Education & Training
- Senior Staff Fellow
- Laboratory of Pathology, NCI (1975)
- Visiting fellow
- Laboratory of Pathology, Fogarty International Foundation, NCI (1974)
- Resident
- Washington Univ School of Medicine (1973)
- Resident
- University of Colorado Medical Center (1972)
- MD
- University of Barcelona (1967)
- Fellow
- National Institute of Health
- Fellow
- National Institute of Health
Board Certifications
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 1974
Research
Overview
Medical Research Interests
ORCID
0000-0002-0906-5033
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
David Rimm, MD, PhD
Dimitra P. Vageli, PhD
Benjamin Doolittle, MD, MA Div
Dieter Lindskog, MD
Gary Friedlaender, MD, BS
Hari Deshpande, MD
Bone Neoplasms
Precancerous Conditions
Publications
2022
Rare Presentation of Rosai‐Dorfman Disease in Soft Tissue: Diagnostic Findings and Surgical Treatment
Betini N, Munger AM, Rottmann D, Haims A, Costa J, Lindskog DM. Rare Presentation of Rosai‐Dorfman Disease in Soft Tissue: Diagnostic Findings and Surgical Treatment. Case Reports In Surgery 2022, 2022: 8440836. PMID: 35402057, PMCID: PMC8986417, DOI: 10.1155/2022/8440836.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSoft tissue Rosai-Dorfman diseaseRosai-Dorfman diseaseExtranodal sitesPlasma cellsNodal Rosai-Dorfman diseaseExtranodal Rosai-Dorfman diseaseEmperipolesis of lymphocytesOrthopedic oncology clinicSoft tissueMinority of casesRDD cellsAssociated lymphadenopathyLymphoplasmacytic infiltrationLymph nodesMixed infiltratePathologic reviewSurgical treatmentOncology clinicChief complaintRare presentationMononuclear cellsSkin changesTreatment paradigmDiagnostic findingsLumbosacral mass
2021
Colorectal Cancer Stem Cell States Uncovered by Simultaneous Single‐Cell Analysis of Transcriptome and Telomeres
Wang H, Gong P, Chen T, Gao S, Wu Z, Wang X, Li J, Marjani SL, Costa J, Weissman SM, Qi F, Pan X, Liu L. Colorectal Cancer Stem Cell States Uncovered by Simultaneous Single‐Cell Analysis of Transcriptome and Telomeres. Advanced Science 2021, 8: 2004320. PMID: 33898197, PMCID: PMC8061397, DOI: 10.1002/advs.202004320.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCancer stem cellsCancer epithelial cellsTumor-initiating cellsCancer stem cell stateEpithelial cellsStem cell stateStem cellsRare cancer stem cellsSimultaneous single-cell analysisHeterogeneity of CSCsSingle-cell analysisNumber variation patternsHippo/YAPDepth transcriptomeSmart-seq2Phylogenetic relationshipsNormal stem cellsCell statesNonproliferative natureColorectal cancerDisplay plasticityDormant stateShort telomeresTelomerase activityTranscriptome
2020
The Progressive Mutagenic Effects of Acidic Bile Refluxate in Hypopharyngeal Squamous Cell Carcinogenesis: New Insights
Sasaki CT, Doukas SG, Costa J, Vageli DP. The Progressive Mutagenic Effects of Acidic Bile Refluxate in Hypopharyngeal Squamous Cell Carcinogenesis: New Insights. Cancers 2020, 12: 1064. PMID: 32344873, PMCID: PMC7281001, DOI: 10.3390/cancers12051064.Peer-Reviewed Original ResearchCitationsConceptsAcidic bileUpper aerodigestive tractAdditional risk factorsBiomarkers of progressionSquamous cell carcinogenesisNF-κB activationNeck malignanciesAerodigestive tractInvasive cancerHistopathological changesRisk factorsHypopharyngeal mucosaEarly neoplasiaMalignant lesionsP53 expressionTranslational studiesVivo modelCell carcinogenesisBileExperimental modelEarly detectionCancerNovel evidenceMutagenic effectsFirst studySynovial Myxoma: Found in Canines, Rabbits, and Now Humans Too?: A Case Report.
Munger AM, Ibe IK, Rottmann D, Conway D, Costa J, Lindskog DM. Synovial Myxoma: Found in Canines, Rabbits, and Now Humans Too?: A Case Report. JBJS Case Connector 2020, 10: e0490. PMID: 32224675, DOI: 10.2106/jbjs.cc.19.00490.Peer-Reviewed Case Reports and Technical NotesAltmetricMeSH Keywords and ConceptsConceptsSynovial myxomaCase reportRight knee painYear old womanCluster of differentiationLow proliferative activityAggressive massKnee painPathologic reviewIntralesional resectionArthroscopic synovectomyKnee aspirationSynovial cellsInfiltrative tumorsMyxoid stromaProliferative activityPainSynovectomyMyxomaSlow growingReportResectionPatientsEffusionHumans
2019
Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications
Sasaki CT, Doukas SG, Costa J, Vageli DP. Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications. Cancer 2019, 125: 3554-3565. PMID: 31310330, DOI: 10.1002/cncr.32369.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHuman hypopharyngeal squamous cell carcinomaAdjacent normal tissuesIL-6Reflux diseaseHypopharyngeal squamous cell carcinomaMiR-375Respective adjacent normal tissuesMiR-21Pilot studyEsophageal reflux diseaseIndependent risk factorNew clinical evidenceSquamous cell carcinomaOncomiR miR-21NF-κB activationMiR-21/miRTumor suppressor miR-375Quantitative polymerase chain reactionMessenger RNABiliary refluxHypopharyngeal carcinogenesisControl patientsLaryngopharyngeal refluxClinical evidenceHypopharyngeal carcinoma
2018
Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB)
Miccio J, Jairam V, Gao S, Augustyn A, Oladeru O, Onderdonk B, Costa J, Han D, Khan S, Friedlaender G, Lindskog D, Deshpande H, Tara H, Osborn H, Roberts K, Patel K. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB). International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e335. DOI: 10.1016/j.ijrobp.2018.07.1028.Peer-Reviewed Original ResearchCitationsA brave new world
Costa J. A brave new world. Virchows Archiv 2018, 473: 141-144. PMID: 29569207, DOI: 10.1007/s00428-018-2338-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords
2017
A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities
Rudkovskaia AA, Lo YC, Brady V, Costa J, Fares WH. A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities. American Journal Of Case Reports 2017, 18: 941-944. PMID: 28855497, PMCID: PMC5590515, DOI: 10.12659/ajcr.903742.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPulmonary tumor thrombotic microangiopathyRight heart catheterizationPulmonary arterial hypertensionTrans-bronchial biopsyPulmonary hypertensionDiagnosis of PTTMPulseless electrical activity cardiac arrestBackground Pulmonary arterial hypertensionGastro-esophageal junction adenocarcinomaNew bilateral pulmonary infiltratesInitiation of trastuzumabMicroscopic tumor embolismSubacute respiratory failureTrans-thoracic echocardiogramTumor thrombotic microangiopathyBilateral pulmonary infiltratesSevere pulmonary hypertensionComplaints of coughRV systolic functionShortness of breathComputed tomography angiographySmall pulmonary vesselsSmooth muscle proliferationPulmonary infiltratesArterial hypertension
2016
Metastatic Papillary Thyroid Carcinoma with Multifocal Synchronous Transformation to Anaplastic Thyroid Carcinoma.
Benedict M, Costa J. Metastatic Papillary Thyroid Carcinoma with Multifocal Synchronous Transformation to Anaplastic Thyroid Carcinoma. Case Reports In Pathology 2016, 2016: 4863405. PMID: 27774331, PMCID: PMC5059640, DOI: 10.1155/2016/4863405.Peer-Reviewed Original Research
2014
Genetic alterations in chondrosarcomas – keys to targeted therapies?
Samuel AM, Costa J, Lindskog DM. Genetic alterations in chondrosarcomas – keys to targeted therapies? Cellular Oncology 2014, 37: 95-105. PMID: 24458248, DOI: 10.1007/s13402-014-0166-8.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBenign cartilaginous lesionsCartilaginous lesionsMalignant transformationIhh/PTHrPTwo-hit scenarioPrimary bone tumorsGenetic alterationsDruggable molecular targetsKey genetic alterationsHuman tumor typesResultsCurrent dataBone tumorsMalignant tumorsSarcoma typesMalignant chondrosarcomasKey molecular changesNormal cell cycle controlTumor typesMalignant cellsChondrosarcoma developmentLesionsMolecular targetsTumorsEarly-stage eventsDifferentiation of chondrocytes
Academic Achievements & Community Involvement
activity Oncology
ResearchDetails01/01/2003 - 12/13/2017Madrid, Community of Madrid, SpainAbstract/SynopsisDr. Costa is a member of the SAB of Centro Nacional Investigaciones Oncológicas (Madrid). In that capacity, he provides input on strategic planning and recruitment of senior leadership and facilitates exchange of students.
activity Tumor Biology
ResearchDetails01/01/2008 - 09/08/2010Barcelona, CT, SpainAbstract/SynopsisDr. Costa collaborates with a colleague at Universitat Pompeu i Fabra, Barcelona. His work involves In Silico Modeling of tumor biology.
activity Colon cancer research
ResearchDetails01/01/2008 - 12/02/2008Paris, Île-de-France, FranceAbstract/SynopsisDr. Costa is engaged in a joint study of transgenic mice developing colon cancer.
activity Liver Cancer Detection
ResearchDetails01/01/2008 - 12/02/2008Barcelona, CT, SpainAbstract/SynopsisDr. Costa collaborates with the Liver Unit at the Hospital Clinic, Barcelona, centered on the early detection of liver cancer related to hepatitis C.
activity Oncology
ResearchDetails01/01/2007 - PresentSpainAbstract/SynopsisDr. Costa is a member of the Board of Directors of Institut Catala d'Oncologia and provides input in strategic planning and recruitment of senior leadership as well as facilitating the exchange of students.
News & Links
News
- June 01, 2006
City vote clears way for building of cancer treatment center
- July 15, 2003
José Costa, M.D.
- April 15, 2000
Work of early cancer virologist celebrated at symposium
- July 15, 1998
Lab testing may allow earlier cancer diagnosis
Related Links
Get In Touch
Contacts
Locations
Department of Pathology
Academic Office
Brady Memorial Laboratory
310 Cedar Street, Ste BML 254A
New Haven, CT 06510
Fax
203.737.4626Appointments
203.785.5803